# RP2 monotherapy achieved an objective response rate (ORR) of 19.0% (4/21 evaluable patients) RP2 in combination with nivolumab achieved an ORR of 19,1%.

*biotech · news · 2026-06-01 · Benzinga*

## Key points

- RP2 monotherapy achieved a 19.0% objective response rate in advanced solid tumor patients.
- RP2 plus nivolumab showed a median duration of response of 22.1 months.
- Tumor regression occurred in both injected and non-injected lesions, indicating systemic immune activation.
- RP1 plus nivolumab led to a 3-year survival rate of 47.8% in anti-PD-1 failed melanoma.

REPL Stock Catalyst: RP2 Data Presentation At ASCO It enrolled 85 heavily pretreated patients with advanced solid tumors. On Sunday, the company said, RP2 monotherapy achieved an objective response rate (ORR) of 19.0% (4/21 evaluable patients). RP2 in combination with nivolumab achieved an ORR of 19.1%, with a disease control rate of 48.9%. Median duration of response (DOR) was not reached in the monotherapy group and was 22.1 months in the combination group. Tumor regression was observed in both injected and non-injected lesions, including in all 3 monotherapy responders who had non-injected lesions, demonstrating a systemic immune response beyond the site of injection. On Saturday, Replimune presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab for anti-PD-1 failed melanoma. RP1 (vusolimogene oderparepvec) plus nivolumab achieved a median overall survival (mOS) of 32.9 months. At 3 years, 47.8% of all treated patients remained alive, rising to 83.5% among responders. The ORR was 33.6%, with a median DOR of 24.8 months; 44.8% of responders maintained their response at 3 years. How Replimune (REPL) Ranks On Momentum And Market Performance Below is the Benzinga Edge scorecard for Replimune Group, highlighting its strengths and weaknesses compared to the broader market: Momentum: Weak (Score: 27.02) — Stock is underperforming the broader market. The Verdict: Replimune Group’s Benzinga Edge signal reveals a momentum-driven story, indicating challenges in maintaining upward price action despite recent gains. Investors should monitor upcoming presentations and earnings closely to gauge future performance. REPL Stock Price Activity: Replimune shares were up 7.02% at $9.295 during premarket trading on Monday, according to Benzinga Pro data. Image via Shutterstock

**Companies:** Replimune Group

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/06/52908786/why-is-replimune-stock-gaining-monday)

---

Canonical: https://newsio.io/n/59b7f290-2dea-4280-94b6-3107e5ed0aa7/rp2-monotherapy-achieved-an-objective-response-rate-orr-of-19-0-421-evaluable-pa
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works